Memantine Accord

Selected form

Memantine Hydrochloride

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Memantine Accord

What is Memantine Accord?

Memantine Accord is a medication used to manage symptoms associated with moderate to severe dementia of the Alzheimer’s type. It belongs to a group of medicines known as anti-dementia drugs.

How it Works

The medication functions as an NMDA-receptor antagonist. In a healthy brain, a chemical messenger called glutamate plays a vital role in signal transmission and memory processes. However, in patients with Alzheimer’s disease, excessive amounts of glutamate can overstimulate the nerve cells, leading to cellular damage and the progression of cognitive symptoms.

Memantine Accord works by attaching to specific receptors on the nerve cells, which helps to normalize the transmission of nerve signals. This mechanism can help improve memory, awareness, and the ability to perform daily functions.

Therapeutic Intent

The primary goal of Memantine Accord is to help maintain cognitive function and stabilize daily activities for individuals in the middle to later stages of Alzheimer’s disease. While it does not cure the underlying condition, it can help manage the cognitive decline and behavioral symptoms that characterize the progression of the disease.

Regulatory References

EPAR: Memantine Accord

What side effects are possible with Memantine Accord?

Possible Side Effects and Safety Information

The safety profile for Memantine Accord is formally defined by regulatory agencies, classifying documented adverse effects by the affected System-Organ Class (SOC) and their frequency of occurrence, based on clinical data and post-marketing surveillance.

Adverse reactions classified as Common (affecting up to 1 in 10 people) include Nervous System Disorders like dizziness and headache, Gastrointestinal effects such as constipation, and hypertension (high blood pressure) [FDA Label]. Effects categorized as Uncommon (affecting up to 1 in 100 people) include psychiatric disturbances like confusion and hallucinations, as well as heart failure [EMA/SmPC].

Documented Safety Considerations

Classification	Example Adverse Reaction	System-Organ Class (SOC)
Common	Dizziness, Somnolence	Nervous System Disorders
Uncommon	Hallucinations, Confusion	Psychiatric Disorders
Uncommon	Heart failure, Vomiting	Cardiac/Gastrointestinal
Very Rare	Seizures/Convulsions	Nervous System Disorders

Serious reactions reported, often in the post-marketing setting where frequency is Not Known, include acute renal failure, hepatitis, and pancreatitis [FDA Label]. The official label notes that patients with severe renal or hepatic impairment may experience altered drug exposure, potentially increasing the risk of adverse effects. Furthermore, co-administration with other NMDA antagonists should be avoided due to the documented risk of increased CNS-related adverse reactions, including pharmacotoxic psychosis [EMA/SmPC]. These regulatory classifications establish the recognized safety and risk parameters for the use of this medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Memantine Accord overdose focuses on documented clinical manifestations and regulator-mandated emergency actions. Overdoses have been associated with a range of reported signs, including tiredness (asthenia), weakness, and diarrhoea, particularly in cases of relative large ingestions.

More severe manifestations documented in regulatory records, especially following acute high-dose exposure (e.g., 2 grams), include coma, confusion, agitation, hallucination, increased blood pressure, bradycardia, and ECG changes. A fatal outcome has been very rarely reported, though the relationship to the drug is noted as unclear in official documents.

When to Seek Immediate Medical Help

The EMA and FDA official instructions require immediate action if a large overdose is taken. Patients or caregivers must contact a doctor or get medical advice promptly, as professional medical attention may be needed for assessment and management. The FDA label further advises contacting a poison control center to determine the latest recommended procedures.

Management and Considerations

Treatment requires symptomatic and general supportive measures. No specific pharmacological antidote is documented in the official prescribing information. The regulatory profile notes that the clearance of memantine may be enhanced by acidification of urine. Accumulation risk is heightened in patients with severe renal impairment and those with conditions that raise urine pH, as these factors can decrease drug elimination and increase plasma levels.

Therapeutic Uses of Memantine Accord

What Memantine Accord Treats: Main Uses and Benefits

Memantine Accord is commonly used to help manage the primary symptoms of moderate-to-severe Alzheimer's disease and related dementias, a category of conditions involving episodic or fluctuating manifestations. The medication is relevant for easing symptoms that interfere with the patient’s functional ability, which is their capacity to perform daily activities such as self-care.

The main indications for this medication are moderate-to-severe Alzheimer's disease. The medication is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient's general well-being during symptomatic phases.

By supporting symptom management across both cognitive and behavioral manifestations (e.g., agitation and restlessness), the treatment may assist with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Support for Symptoms of Cognitive and Functional Strain

Regulatory References

European Medicines Agency (EMA) overview

Eligibility and Restrictions for Use

Eligibility Status and Restrictions

Memantine Accord is officially approved for use in adult patients (aged 18 years and over) diagnosed with moderate-to-severe Alzheimer's disease. Regulatory bodies have established strict limits on eligibility.

Absolute Contraindications

Use is prohibited in individuals with known hypersensitivity to memantine hydrochloride or any of its excipients. Patients diagnosed with rare hereditary problems, such as galactose intolerance or Lapp lactase deficiency, are also contraindicated due to the tablet's excipient content.

Conditional Use and Exclusions

The medicine is not recommended for children and adolescents below 18 years as data on safety and efficacy are insufficient. Treatment is also not recommended for patients with severe hepatic impairment. Individuals with severe renal impairment are eligible, but use is restricted and requires a mandatory dose adjustment.

Pregnancy and Comorbidities

Memantine Accord is not recommended during pregnancy unless clearly necessary. Women taking the medicine should not breastfeed. Patients with a history of epilepsy or certain uncontrolled cardiovascular conditions require close medical supervision.

What should I know about interactions with other medicines?

The official interaction profile of Memantine Accord is governed by pharmacokinetic and pharmacodynamic constraints defined in regulatory documents.

Interaction Scope

Interaction-related restrictions require that co-administration with other NMDA receptor antagonists, specifically amantadine, ketamine, and dextromethorphan, be avoided due to the documented risk of increased central nervous system-related adverse reactions. The mechanistic basis of interactions involves Renal Cationic Transport Competition and Urine pH-Dependent Clearance Modification. Specific interacting medicines that compete for the renal cationic transport system, such as cimetidine, quinidine, ranitidine, and nicotine, may lead to a potential risk of increased plasma levels of memantine.

Interaction Classifications (High-Level)

Regulatory documents define a Potential for Accumulation risk with substances or conditions that alkalinize urine. Urinary Alkalinizing Agents, including Sodium Bicarbonate or Carbonic Anhydrase Inhibitors, can significantly reduce memantine clearance. Population-specific interaction notes confirm this accumulation risk is also present in clinical states such as Renal Tubular Acidosis or severe Urinary Tract Infections. Other pharmacodynamic interactions mean the effects of L-dopa and dopaminergic agonists may be enhanced, while effects of barbiturates and neuroleptics may be reduced. Isolated cases of INR increases have been reported with co-administration of warfarin.

Mechanism of Action

Targeted Modulation of Excitatory Signaling

Memantine's mechanism centers on the N-methyl-D-aspartate (NMDA) receptor, the primary target for the excitatory neurotransmitter, glutamate, in the brain. The molecule functions as an uncompetitive antagonist by physically blocking the ion channel pore of the receptor, but only when the receptor is already open and active. This molecular action modulates the intensity of glutamatergic output within the central nervous system.

Selective Control of Pathological Activation

A core aspect of the mechanism is its functional profile, driven by its low affinity and voltage-dependent blockade. This kinetic profile ensures that memantine preferentially blocks the sustained, chronic NMDA receptor activity associated with sustained neuronal depolarization (pathological activation). Due to its rapid dissociation rate, the molecule permits normal, transient signaling, allowing routine physiological synaptic activity to persist.

Regulating Calcium-Mediated Excitotoxicity

By physically obstructing the NMDA receptor channel, memantine limits the excessive and prolonged flow of calcium ions ( Ca^2+) into the nerve cell. This reduction in intracellular Ca^2+ overload regulates the downstream effects of excitotoxicity—a process where chronic overstimulation causes cellular dysfunction. The physiological consequence of this blockade is the maintenance of Ca^2+ homeostasis, which influences functional communication pathways.

Dosage and Administration Information

Memantine Accord is administered by the oral route as a film-coated tablet and its initiation must be supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. A caregiver is also required to monitor the patient's daily intake.

Official Titration and Dosing Protocol

Treatment is typically initiated at the lowest dose and gradually increased over the first four weeks. The goal of this structured dosing, known as titration, is to achieve the standard maintenance dose of 20 mg per day while observing patient tolerance. The maximum daily intake of memantine for the immediate-release tablet formulation is 20 mg.

Week	Daily Dose
Week 1	5 mg
Week 2	10 mg
Week 3	15 mg
Week 4 onwards	20 mg (Maintenance Dose)

Administration Rules and Adjustments

The tablets can be taken with or without food and should be administered consistently at the same time each day. The 10 mg film-coated tablets are scored, allowing them to be divided to facilitate the 5 mg initial and titration doses.

If a single dose is missed, patients should take the next scheduled dose without doubling the amount. If the medicine is not taken for several days, treatment may need to be resumed at a lower dose and re-titrated. For individuals with severe renal impairment (creatinine clearance of 5–29 mL/min), the maximum recommended daily dose is reduced to 10 mg. The benefit of the medicine should be reassessed on a regular basis, preferably within three months after beginning treatment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Memantine Accord

Evidence for use in Moderate-to-Severe Alzheimer's Disease

The foundation of research for Memantine Accord primarily rests on multiple Randomized Controlled Trials (RCTs). These short-term, controlled studies were designed to evaluate the symptomatic patterns in individuals diagnosed with moderate-to-severe Alzheimer's disease (AD). The research explored the medicine alone (as monotherapy) and in combination with other established Alzheimer's treatments, providing the evidence base for the regulatory decision on use in symptomatic evaluation for this group.

In these studies, researchers monitored changes using specific assessment tools. Outcomes were related to global status, which reflects an overall impression of the patient's condition, as well as changes in cognitive function using specialized scales designed for severely impaired populations. Studies reported measurements observed on these scales during the study period, which often spanned between 24 and 28 weeks.

Studies on Specific Clinical Measures

Research into functional ability and behavioral changes

Research examined scales that reflect a person's functional ability during the study periods, which includes outcomes reflecting daily functioning or activity level. These outcomes reflecting daily functioning were observed in studies evaluating daily-life functioning in participants.

Additionally, clinical trials monitored behavioral manifestations, such as changes in agitation, aggression, or irritability, using standardized inventory tools. Studies monitored patterns in these behavioral measures over defined time intervals. Research highlights changes measured during the study period, contributing to the broader evidence landscape.

Long-Term Studies and Follow-up Duration

The primary, most controlled research trials were short-term, with observation periods often spanning six to seven months. This means that the most consistent evidence regarding the initial symptomatic patterns and measured changes applies only to this limited follow-up duration.

Evidence for long-term effects are not fully established through similarly rigorous, long-duration controlled trials. While some studies, often observational in nature, have explored long-term use, the evidence quality varies across studies. There is limited information for long-term outcomes regarding the maintenance of measured symptomatic patterns over multiple years.

What is Still Uncertain about the Research

A key limitation is that follow-up durations were limited in the main controlled studies, and long-term outcomes are not fully established. Evidence quality varies across studies when examining certain specific symptoms or patient subgroups.

Additionally, while trials included a specific range of older adults, the results apply only to the populations studied, and data for certain groups remain insufficient. Finally, the study of outcomes related to nursing home placement remains sparse in the controlled research literature.

Frequently Asked Questions (FAQ)

Common questions about Memantine Accord (FAQ)

Q: Is Memantine Accord the same as other memantine brands I've heard of?

Memantine Accord is a brand name for a medicine that contains the active substance memantine hydrochloride. According to regulatory documentation, many different generic and brand products use this exact same active ingredient for treatment.

Q: What makes Memantine Accord different from Aricept or other Alzheimer's drugs?

Memantine Accord is classified as an NMDA-receptor antagonist, which is a distinct therapeutic approach for Alzheimer's. This medicine modulates excitatory signals in the brain. This mechanism differs from cholinesterase inhibitors (like donepezil), which work by helping to increase levels of the brain chemical acetylcholine.

Q: Does Memantine Accord cause weight gain or weight loss?

Official reports from clinical trial data for memantine have listed increased weight as an uncommon adverse reaction. This means it has been observed in a small percentage of patients during studies. Weight changes are not listed among the most frequently reported common side effects (those affecting more than 1 in 10 people).

Q: Does alcohol consumption affect how Memantine Accord works?

Official guidance notes that the combined use of memantine with alcohol has not been systematically evaluated. Patients should be aware that alcohol may potentially worsen some central nervous system-related side effects, such as dizziness or headaches.

Q: What happens if I accidentally miss a dose of Memantine Accord?

If a single dose is missed, the official guidance is to skip that dose and take the next scheduled dose as planned. The official protocol advises against taking a double amount to compensate for the missed one. If the medicine is not taken for several days, official guidance advises that treatment may need to be resumed at a lower dose and re-titrated under professional supervision.

Q: Does Memantine Accord help with memory loss or just slow down decline?

Memantine Accord is indicated for the symptomatic treatment of moderate to severe Alzheimer's disease. The medicine works by regulating nerve signals important in learning and memory. The intended action is to manage symptoms and stabilize the neuronal environment, aiming to support the maintenance of existing cognitive abilities.

Q: Can Memantine Accord be used for types of dementia other than Alzheimer's?

According to official regulatory approval, Memantine Accord is indicated only for the treatment of moderate to severe dementia of the Alzheimer's type. It is not approved for use in other forms of dementia.

Q: Are there any major diet restrictions or foods to avoid while on Memantine Accord?

Regulatory documents state that Memantine Accord tablets can be taken with or without food. There are no specific dietary restrictions mentioned in the official instructions regarding common food intake.

Q: Can younger people with severe cognitive issues sometimes be prescribed Memantine Accord?

The medicine is officially approved for use only in adult patients aged 18 years and over. It is not recommended for use in children and adolescents below 18 years due to a lack of safety and efficacy data in that population.

Q: Are there any natural supplements or vitamins that interact with Memantine Accord?

Regulatory documents explicitly warn that memantine can interact with other medicines and substances that make the urine alkaline. Patients are advised in regulatory documents to disclose all prescription and non-prescription medicines, including supplements and vitamins, to their healthcare professional due to the potential for interactions.

Q: Does taking Memantine Accord affect driving or operating machinery?

Due to the nature of moderate to severe Alzheimer’s disease, the ability to drive and use complex machinery is already compromised. Furthermore, official product information warns that patients should take special care due to the medicine's minor to moderate influence on these abilities.

Q: Can Memantine Accord help with behavioral symptoms of Alzheimer's, like agitation?

Clinical trials evaluate effects using tools that measure changes in functional ability and global status. While studies have monitored behavioral manifestations, official product information does not list agitation or aggression as a specific indication.

Q: Is there a generic version of Memantine Accord available?

Yes, the active ingredient in this medicine, memantine hydrochloride, is the same as that found in many generic versions and other brand formulations, all approved by regulatory bodies.

Q: Does Memantine Accord affect sleep patterns or cause insomnia?

The official list of side effects from clinical trials notes that somnolence (sleepiness or drowsiness) is a Common side effect, potentially affecting up to 1 in 10 people. Any changes in sleep patterns should be addressed with a healthcare professional.

Q: Are headaches a common concern for new users of Memantine Accord?

Headache is listed as a Common side effect in clinical trials, meaning it may affect up to 1 in 10 people during treatment. Due to the risk of initial adverse reactions, the medicine is typically started at a lower dose and gradually increased.

Q: Does Memantine Accord impact blood pressure or heart rhythm?

Official safety data lists hypertension (high blood pressure) as a Common side effect. More seriously, heart failure is listed as an Uncommon side effect, meaning it may affect up to 1 in 100 people. The management of these effects is part of the ongoing clinical supervision.

Q: What's the difference between Memantine Accord tablets and oral solution?

Memantine Accord is specifically manufactured as film-coated tablets. Other formulations of memantine, such as oral solution, may be available from different manufacturers, and these typically have their own unique administration instructions.

--UNSURE

Q: Has Memantine Accord been studied in people with mild cognitive impairment (MCI)?

The medicine is officially approved for the treatment of moderate-to-severe Alzheimer's disease. Regulatory documents do not list mild cognitive impairment (MCI) as an approved or recommended indication for this medication.

Q: Is it normal to feel a bit nauseous when first starting the medication?

Official side effect information lists Vomiting as an Uncommon adverse reaction. While not a common effect, the medicine is typically started with a gradual increase in dose to mitigate the risk of initial adverse reactions.

Q: What is the ultimate goal of treatment with Memantine Accord?

The official goal of treatment with Memantine Accord is the symptomatic management of moderate to severe Alzheimer's disease. This is intended to help stabilize the neuronal environment and support the maintenance of existing cognitive abilities.

Q: Does Memantine Accord interact with common cold or flu medicines?

Co-administration with other NMDA receptor antagonists, such as dextromethorphan—a component often found in over-the-counter cough and cold medicines—should be avoided. Combining these medicines carries a documented risk of increasing central nervous system-related adverse reactions.

Q: Is Memantine Accord a curative treatment for Alzheimer's disease?

No. Memantine Accord is indicated for the symptomatic treatment of the disease, according to official regulatory documents, and is not classified as a cure.

Q: Do I need regular blood tests while taking Memantine Accord?

Regulatory guidance advises that the tolerance and dose should be reassessed on a regular basis. In patients with severe kidney impairment, specific dose restrictions apply, and monitoring of kidney function may be performed as part of clinical supervision.

Q: Why is family support important when someone is taking Memantine Accord?

Regulatory guidance requires that the start of therapy should only happen if a caregiver is available. This caregiver is needed to regularly monitor the patient's intake of the medicine, ensuring consistent administration as part of the treatment protocol.

How should Memantine Accord be stored and disposed of?

How to Store and Dispose of Memantine Accord

This section outlines the mandatory storage and disposal rules for Memantine Accord, based strictly on official regulatory labeling.

Storage Requirements

Memantine Accord film-coated tablets do not require any special storage conditions when kept in the original sealed package. However, the medicine must always be stored out of the sight and reach of children.

Container and Stability

The product must not be used after the printed expiry date (EXP). If the medicine is supplied in a bottle, the contents should be used within 6 months after the bottle is opened.

Disposal Instructions

Expired or unused Memantine Accord must not be thrown away via wastewater or household waste. The proper procedure is to ask a pharmacist for guidance on disposal to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.